GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents

Background: GLP‑1 receptor agonists (GLP‑1RAs) are effective for type 2 diabetes and obesity and engage central stress and reward pathways (HPA axis; mesolimbic dopamine). Psychiatric signals have been reported in some settings. Objective :To narratively synthesize evidence on neuropsychiatric effects of GLP‑1RAs—mood, anxiety, suicidality, reward processing, substance use, and migraine—and to consider genetic/epigenetic moderators (e.g., hypodopaminergia/reward deficiency syndrome).Evidence: Mechanistic and imaging studies demonstrate GLP‑1 engagement of HPA and reward circuitry; animal work suggests acute anxiogenic responses with mixed chronic effects. Pharmacovigilance datasets (FAERS/EudraVigilance) show signals for headache, dizziness, sensory changes, and less consistently for depression/anxiety/suicidality; such data are hypothesis‑generating and not causal. Clinical trials and meta‑analyses report heterogeneous outcomes, including small antidepressant effects in some T2DM cohorts. Conclusions: Neuropsychiatric outcomes with GLP‑1RAs appear context‑dependent. Individuals with hypodopaminergic biology may be vulnerable to reward blunting/anxiety, whereas others may experience mood benefits. A pragmatic approach is screen–stratify–monitor, with slow titration and prompt adjustment if psychiatric signals emerge. Prospective, genotype‑informed studies are needed to identify who benefits or is harmed and why.